Alzheimer's disease survey

Please indicate your degree: Other...

Please indicate your specialty: Other...

Amyloid imaging is appropriate in which of the following patients? *

Patient with persistent or progressive unexplained mild cognitive impairment

Patient who meets core clinical criteria for AD but presents with atypical clinical course

Patient with progressive dementia and atypical early onset

All of the above

None of the above

Which of the following investigational drugs inhibits the β-secretase enzyme from cleaving the amyloid precursor protein and thus prevents buildup of Aβ?

Which of the following investigational drugs inhibits the β-secretase enzyme from cleaving the amyloid precursor protein and thus prevents buildup of Aβ? *

Which of the following drugs is an antibody directed against Aβ?

Which of the following drugs is an antibody directed against Aβ? *

Solanezumab

Daclizumab

Rituximab

All of the above

None of the above

Please rate your agreement with the following statements. *

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree	N/A
I can describe the core clinical criteria described by the National Institute on Aging-Alzheimer’s Association to diagnose AD.	I can describe the core clinical criteria described by the National Institute on Aging-Alzheimer’s Association to diagnose AD. - Strongly Disagree	I can describe the core clinical criteria described by the National Institute on Aging-Alzheimer’s Association to diagnose AD. - Disagree	I can describe the core clinical criteria described by the National Institute on Aging-Alzheimer’s Association to diagnose AD. - Neutral	I can describe the core clinical criteria described by the National Institute on Aging-Alzheimer’s Association to diagnose AD. - Agree	I can describe the core clinical criteria described by the National Institute on Aging-Alzheimer’s Association to diagnose AD. - Strongly Agree	I can describe the core clinical criteria described by the National Institute on Aging-Alzheimer’s Association to diagnose AD. - N/A
I am up-to- date on current biomarker research in Alzheimer’s disease.	I am up-to- date on current biomarker research in Alzheimer’s disease. - Strongly Disagree	I am up-to- date on current biomarker research in Alzheimer’s disease. - Disagree	I am up-to- date on current biomarker research in Alzheimer’s disease. - Neutral	I am up-to- date on current biomarker research in Alzheimer’s disease. - Agree	I am up-to- date on current biomarker research in Alzheimer’s disease. - Strongly Agree	I am up-to- date on current biomarker research in Alzheimer’s disease. - N/A
I can summarize the recent data on the safety and efficacy of anti-Aβ immunotherapies for AD.	I can summarize the recent data on the safety and efficacy of anti-Aβ immunotherapies for AD. - Strongly Disagree	I can summarize the recent data on the safety and efficacy of anti-Aβ immunotherapies for AD. - Disagree	I can summarize the recent data on the safety and efficacy of anti-Aβ immunotherapies for AD. - Neutral	I can summarize the recent data on the safety and efficacy of anti-Aβ immunotherapies for AD. - Agree	I can summarize the recent data on the safety and efficacy of anti-Aβ immunotherapies for AD. - Strongly Agree	I can summarize the recent data on the safety and efficacy of anti-Aβ immunotherapies for AD. - N/A
I can summarize the recent data on the safety and efficacy of BACE inhibitors for AD.	I can summarize the recent data on the safety and efficacy of BACE inhibitors for AD. - Strongly Disagree	I can summarize the recent data on the safety and efficacy of BACE inhibitors for AD. - Disagree	I can summarize the recent data on the safety and efficacy of BACE inhibitors for AD. - Neutral	I can summarize the recent data on the safety and efficacy of BACE inhibitors for AD. - Agree	I can summarize the recent data on the safety and efficacy of BACE inhibitors for AD. - Strongly Agree	I can summarize the recent data on the safety and efficacy of BACE inhibitors for AD. - N/A

Please indicate how frequently you perform the following clinical practice strategies. *

	Never	Not Often	Sometimes	Often	Always	N/A
I perform a cognitive assessment using a validated assessment tool during the annual wellness visit for patients aged ≥65 years.	I perform a cognitive assessment using a validated assessment tool during the annual wellness visit for patients aged ≥65 years. - Never	I perform a cognitive assessment using a validated assessment tool during the annual wellness visit for patients aged ≥65 years. - Not Often	I perform a cognitive assessment using a validated assessment tool during the annual wellness visit for patients aged ≥65 years. - Sometimes	I perform a cognitive assessment using a validated assessment tool during the annual wellness visit for patients aged ≥65 years. - Often	I perform a cognitive assessment using a validated assessment tool during the annual wellness visit for patients aged ≥65 years. - Always	I perform a cognitive assessment using a validated assessment tool during the annual wellness visit for patients aged ≥65 years. - N/A
I recommend preventive or early recognition trials to your patients who are at high risk for Alzheimer’s disease.	I recommend preventive or early recognition trials to your patients who are at high risk for Alzheimer’s disease. - Never	I recommend preventive or early recognition trials to your patients who are at high risk for Alzheimer’s disease. - Not Often	I recommend preventive or early recognition trials to your patients who are at high risk for Alzheimer’s disease. - Sometimes	I recommend preventive or early recognition trials to your patients who are at high risk for Alzheimer’s disease. - Often	I recommend preventive or early recognition trials to your patients who are at high risk for Alzheimer’s disease. - Always	I recommend preventive or early recognition trials to your patients who are at high risk for Alzheimer’s disease. - N/A

If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following:

First Name:

Last Name:

Email:

You are here

Alzheimer's disease survey